Evidence map›Paper›PMID 36267620›Full record

ArticleFrontiers in medicine2022

Bone marrow stromal cell antigen-1 (CD157) regulated by sphingosine kinase 2 mediates kidney fibrosis.

Tsuyoshi Inoue, Yasuna Nakamura, Shinji Tanaka, Takahide Kohro, Lisa X Li, Liping Huang, Junlan Yao, Suzuka Kawamura, Reiko Inoue, Hiroshi Nishi and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A role for plasma membrane CaPflugers Archiv : European journal of physiology · 2024
    Article
  5. Review
  6. Bone marrow stromal cell antigen-1 deficiency protects from acute kidney injury.American journal of physiology. Renal physiology · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Tsuyoshi InoueDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Yasuna NakamuraDepartment of Physiology of Visceral Function and Body Fluid, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Shinji TanakaDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Takahide KohroDepartment of Clinical Informatics/Cardiology, Jichi Medical University, Tochigi, Japan.
Lisa X LiDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Liping HuangDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Junlan YaoDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Suzuka KawamuraDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Reiko InoueDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroshi NishiDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Daichi FukayaDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Rie UniDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sho HasegawaDivision of Chronic Kidney Disease Pathophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Reiko InagiDivision of Chronic Kidney Disease Pathophysiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ryusuke UmeneDepartment of Physiology of Visceral Function and Body Fluid, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Chia-Hsien WuDepartment of Physiology of Visceral Function and Body Fluid, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Hong YeDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Amandeep BajwaDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
Diane L RosinDepartment of Pharmacology, University of Virginia, Charlottesville, VA, United States.
Katsuhiko IshiharaDepartment of Immunology and Molecular Genetics, Kawasaki Medical School, Okayama, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Youichiro WadaIsotope Science Center, The University of Tokyo, Tokyo, Japan.
Mark D OkusaDivision of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, United States.
University of Virginia · USThe University of Tokyo · JPNagasaki University · JPJichi Medical University · JPKawasaki Medical School · JP

Funding

Sphingolipids in Acute Kidney Injury and Disease ProgressionR01DK085259 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2023
$5.0M
Leukocyte Trafficking in Acute Renal FailureR01DK062324 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI OKUSA, MARK DOUGLAS · 2003 to 2016
$4.4M
MBF Bioscience and Zeiss Microscope System for Stereology and Tissue MorphologyS10RR026799 · NCRR · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2010
$278k
NCRR NIH HHS S10 RR026799NIDDK NIH HHS R01 DK062324NIDDK NIH HHS R01 DK085259
6 · The paper itself

Abstract

Chronic kidney disease is a progressive disease that may lead to end-stage renal disease. Interstitial fibrosis develops as the disease progresses. Therapies that focus on fibrosis to delay or reverse progressive renal failure are limited. We and others showed that sphingosine kinase 2-deficient mice (

Indexed as

ADP-ribosyl cyclaseBST-1/CD157fibrosisGPI-linked proteinskidney

Identifiers

PMID36267620
PMCPMC9576863
OpenAlexW4301398281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.